Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05804032 |
Recruitment Status :
Recruiting
First Posted : April 7, 2023
Last Update Posted : January 10, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Myeloma | Drug: Isatuximab Drug: Lenalidomide Drug: Bortezomib Drug: Dexamethasone | Phase 3 |
Prospective, multicentre, randomised, parallel group, open, phase III clinical trial, for patients with confirmed diagnosis of untreated multiple myeloma requiring systemic therapy.
Investigational Medicinal Product: Isatuximab, subcutaneous administration via a wearable injector system.
Randomization: Patients are randomized in one of 2 study arms (A or B) before induction therapy. Patients randomized in arm A will receive 3 cycles of the monoclonal antibody isatuximab intravenously, combined with RVd regimen (Lenalidomide, Bortezomib, Dexamethasone). Each cycle will last for 42 days. Patients in arm B will receive 3 cycles RVd plus isatuximab subcutaneously. After induction therapy, patients will receive standard intensification (usually cyclophosphamide-based mobilization therapy, stem cell collection and high-dose melphalan followed by autologous stem cell transplantation (HDM/ASCT)). End of study will be after the first HDM/ASCT.
There is one primary objective:
Demonstration of non-inferiority of subcutaneous (SC) isatuximab compared to intravenous (IV) isatuximab, both in combination with RVd, with respect to rates of VGPR or better after induction therapy (according to standard International Myeloma Working Group (IMWG) response criteria).
Key secondary objectives are:
- Comparison of patient-reported outcomes (PRO) regarding route of administration of isatuximab (SC vs. IV) on induction therapy as assessed by modified CTSQ (modified 9-item questionnaire).
- Non-inferiority of rates of MRD negativity (assessed by NGS from BMA; sensitivity 10^-5) independent of standard IMWG response after induction therapy.
The duration of the trial for each patients is expected to be approximately 10 months (induction and intensification treatment).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 514 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Phase III Non-inferiority Trial Assessing Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma. |
Actual Study Start Date : | April 14, 2023 |
Estimated Primary Completion Date : | July 24, 2025 |
Estimated Study Completion Date : | July 24, 2026 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Arm A - Intravenous isatuximab
Patients in arm A are treated with 3 cycles RVd + i.v. isatuximab, followed by a standard intensification and autologous stem cell transplantation.
|
Drug: Isatuximab
IV isatuximab will be administered weekly in the first cycle (Cycle 1) on days 1, 8, 15, 22, 29, and biweekly on the 2 subsequent cycles at days 1, 15 and 29, at the dose of 10 mg/kg.
Other Name: Sarclisa Drug: Lenalidomide Both arms: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 Drug: Bortezomib Both arms: 1.3 mg/m^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
Other Name: Velcade Drug: Dexamethasone 20 mg per os on day 1-2, 4-5, 8-9, 11-12, 15; and 22-23, 25-26, 29-30, 32-33 in induction cycles 1-3. |
Experimental: Arm B - Subcutaneous isatuximab
Patients in arm B are treated with 3 cycles RVd + s.c. isatuximab, followed by a standard intensification and autologous stem cell transplantation.
|
Drug: Isatuximab
SC isatuximab will be administered on days 1, 8, 15, 22, 29 of cycle 1, and on days 1, 15 and 29 of cycles 2-3, at the dose of 1400 mg
Other Name: Sarclisa Drug: Lenalidomide Both arms: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 Drug: Bortezomib Both arms: 1.3 mg/m^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
Other Name: Velcade Drug: Dexamethasone 20 mg per os on day 1-2, 4-5, 8-9, 11-12, 15; and 22-23, 25-26, 29-30, 32-33 in induction cycles 1-3. |
- Demonstration of non-inferiority of subcutaneous (SC) isatuximab compared to intravenous (IV) isatuximab, both in combination with RVd. [ Time Frame: 18 weeks after start of study treatment ]Rates of VGPR or better (according to standard IMWG response criteria), defined as proportion of patients with at least VGPR after induction therapy (according to standard International Myeloma Working Group (IMWG) response criteria).
- Quality of life compared between Arm A and B. [ Time Frame: 18 weeks after start of study treatment ]Comparison of PRO (patient-reported outcome) regarding route of administration of isatuximab (SC vs. IV) on induction therapy as assessed by modified CTSQ (modified 9-item questionnaire)
- Non-inferiority of rates of MRD negativity in Arm B compared to Arm A [ Time Frame: 18 weeks after start of study treatment ]Rates of NGS-MRD negativity (sensitivity 10^-5, from bone marrow aspirate) after induction therapy
- Rates of MRD negativity by NGS and NGF (sensitivity 10^-5, from BMA) independent of standard IMWG response after first HDM/ASCT [ Time Frame: 18 weeks (timepoint "after induction") or 35 weeks (timepoint "after first HDM/ASCT") after start of study treatment ]defined as proportion of negative patients with the corresponding MRD method (NGS or NGF) at the defined timepoint (after induction therapy or first HDM/ASCT)
- Rates of best overall response to treatment (BOR) [ Time Frame: Depending on the timepoint of best response out of all response assessments, up to 10 months from randomization ]proportion of patients with BOR (at least PR or better) to treatment until end of study (based on timepoints post induction cycle 2 and 3, prior to HDM/ASCT and post first HDM/ASCT)
- Progression-free survival (PFS) [ Time Frame: Until EOS (28 months after start of study) ]Time from randomization (at study inclusion) to progression or death from any cause whichever occurs first
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Confirmed diagnosis of untreated MM requiring systemic therapy (diagnostic criteria according to IMWG)
- Patient is eligible for high-dose melphalan (200 mg/m^2 melphalan) and autologous stem cell transplantation
- Measurable MM disease according to IMWG criteria, defined as any quantifiable monoclonal protein value, defined by at least one of the following three measurements: serum M-protein ≥ 10 g/L; urine light-chain (M-protein) of ≥ 200 mg/24 hours; involved FLC level ≥ 10 mg/dL provided sFLC ratio is abnormal
- Age 18-70 years at trial inclusion
Exclusion Criteria:
- Patient has known hypersensitivity (or contraindication) to any of the components of study therapy
- Systemic amyloid light-chain amyloidosis (except for localized AL amyloidosis limited to the skin or the bone marrow)
- Plasma cell leukemia
- Previous chemotherapy or radiotherapy during the past 5 years except local radiotherapy in case of local MM progression
- Severe cardiac dysfunction (NYHA classification III-IV)
- Patients with active or uncontrolled hepatitis B or C or detectable liver disease due to hepatitis B or C
- HIV positivity
- Patients with active, uncontrolled infections
- Patients with severe renal insufficiency or requiring hemodialysis
- Patients with peripheral neuropathy or neuropathic pain, grade 2 or higher (as defined by the NCI Common Terminology Criteria for Adverse Events)
- Patients with a history of any active malignancy during the past 5 years with the exception of following malignancies after curative therapy: basal cell carcinoma of the skin, squamous cell skin carcinoma, stage 0 cervical carcinoma or any in situ malignancy
- Platelet count < 75 x 10^9/L
- Haemoglobin ≤ 8.0 g/dL, unless related to MM
- Absolute neutrophil count (ANC) < 1.0 x 10^9/L (the use of colony stimulating factors within 14 days before the test is not allowed)
- Corrected serum calcium > 14 mg/dL (> 3.5 mmol/L)
- Pregnancy and lactation
For further details on inclusion/exclusion criteria please refer to the study protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05804032
Contact: Hartmut Goldschmidt, Prof. | +49 6221 568198 | s.gmmg@med.uni-heidelberg.de |
Principal Investigator: | Hartmut Goldschmidt, Prof. | GMMG study group |
Responsible Party: | Prof. Dr. Hartmut Goldschmidt, Principal Investigator, University of Heidelberg Medical Center |
ClinicalTrials.gov Identifier: | NCT05804032 |
Other Study ID Numbers: |
GMMG-HD8/DSMM XIX |
First Posted: | April 7, 2023 Key Record Dates |
Last Update Posted: | January 10, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Neoplasms Paraproteinemias Lymphoproliferative Disorders Immunoproliferative Disorders Lenalidomide |
Bortezomib Dexamethasone Isatuximab Monoclonal antibodies |
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Dexamethasone |
Lenalidomide Bortezomib Antibodies, Monoclonal Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Immunologic Factors |